Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Merck Sharp & Dohme Corp.
C C C C C C C C C C C
C07D C07D C07D C07D C07D C07D C07D C07D C07D C07D C07D
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Joey L. Harold B. Solomon J. Michael Ryan Wing-Kun Ling John Weiguo Blair T. Hakan Vladimir Joanna L. Thomas H. David Annunziato Peter H. Anmol Ping Mitchell Henry Santhosh F.
Methot Wood Kattar Ellis Chau Tong Acton Liu Lapointe Gunaydin Simov Chen Graham Candito Fuller Gulati Liu Keylor Neelamkavil